Predicting the outcomes of pulmonary hypertension is a breathtaking task

The following parameters are used for risk assessment in PAH: (a) clinical signs of right heart failure, (b) progression of symptoms, (c) syncope, (d) World Health Organization (WHO) functional class, (e) 6-minute walking distance, (f) cardiopulmonary exercise testing, (g) N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels, (h) imaging (echocardiography, cardiac magnetic resonance imaging), and (i) invasive haemodynamics [1]. An increase in PA size over time can be a feature of PH but is not necessarily an indication of increasing PA pressure; therefore, the correlation of PH with mean pulmonary arterial pressure is weak [6]. [...]within PH subgroups, different vascular and cardiac configurations are observed with CT, reflecting the heterogeneity of PH. [...]in CTEPH patients who are technically operable, pulmonary endarterectomy is the treatment of choice, while balloon pulmonary angioplasty or medical treatment with a guanylate cyclase stimulator should be considered for technically inoperable CTEPH patients.